期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

State of the art biological therapies in pancreatic cancer 被引量：3

State of the art biological therapies in pancreatic cancer
下载PDF
导出
摘要 Pancreatic ductal adenocarcinoma(PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstrate efficacy in late phase clinical trials, despite the better understanding of PDAC molecular biology generated by large cancer sequencing initiatives in the past decade. Eroltinib(a small-molecule tyrosine-kinase inhibitor of epidermal growth factor receptor) plus gemcitabine is the only schedule with a biological agent approved for advanced pancreatic cancer, but it has resulted in a very modest survival benefit in unselected patients. In our work, we report a summary of the main clinical trials(closed and ongoing) that refer to biological therapy evaluation in pancreatic cancer treatment. Pancreatic ductal adenocarcinoma(PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstrate efficacy in late phase clinical trials, despite the better understanding of PDAC molecular biology generated by large cancer sequencing initiatives in the past decade. Eroltinib(a small-molecule tyrosine-kinase inhibitor of epidermal growth factor receptor) plus gemcitabine is the only schedule with a biological agent approved for advanced pancreatic cancer, but it has resulted in a very modest survival benefit in unselected patients. In our work, we report a summary of the main clinical trials(closed and ongoing) that refer to biological therapy evaluation in pancreatic cancer treatment.
作者 mariacristina di marco elisa grassi sandra durante silvia vecchiarelli andrea palloni marina macchini riccardo casadei claudio ricci riccardo panzacchi donatella santini guido biasco
机构地区 department of experimental department of medical and surgical sciences pathology unit
出处 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2016年第1期55-66,共12页 世界胃肠肿瘤学杂志（英文版）（电子版）
关键词 PANCREATIC cancer Molecular characterization TARGETED therapy EPIDERMAL growth factor receptorinhibitors EMBRYONIC pathway INHIBITORS Antiangiogenictherapies Pancreatic cancer Molecular characterization Targeted therapy Epidermal growth factor receptor inhibitors Embryonic pathway inhibitors Antiangiogenic therapies
分类号 R735.9 [医药卫生—肿瘤]
  • 相关文献

参考文献79

  • 1Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA CancerJ Clin 2015; 65: 5-29 [PMID: 25559415 DOI: 10.3322/caac.21254].
  • 2Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, AbramsRA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resectedadenocarcinoma of the pancreas-616 patients: results, outcomes,and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579[PMID: 11307091].
  • 3Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R,Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de laFouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine formetastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825[PMID: 21561347 DOI: 10.1056/NEJMoa1011923].
  • 4Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, MooreM, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, ReniM, Dowden S, Laheru D, Bahary N, Ramanathan RK, TaberneroJ, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J,Renschler MF. Increased survival in pancreatic cancer with nabpaclitaxelplus gemcitabine. N Engl J Med 2013; 369: 1691-1703[PMID: 24131140 DOI: 10.1056/NEJMoa1304369].
  • 5Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S,Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, DingK, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W.Erlotinib plus gemcitabine compared with gemcitabine alone inpatients with advanced pancreatic cancer: a phase III trial of theNational Cancer Institute of Canada Clinical Trials Group. J ClinOncol 2007; 25: 1960-1966 [PMID: 17452677].
  • 6Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S,Brandi G, Biasco G. Metastatic pancreatic cancer: is gemcitabinestill the best standard treatment- (Review). Oncol Rep 2010; 23:1183-1192 [PMID: 20372829].
  • 7Chang DK, Grimmond SM, Biankin AV. Pancreatic cancergenomics. Curr Opin Genet Dev 2014; 24: 74-81 [PMID: 24480245DOI: 10.1016/j.gde.2013.12.001].
  • 8Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, BernabéRR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A,Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, KolarP, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G,Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, ShibataT, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM,Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG,Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolás P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, WiesnerGL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, ClémentB, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, HudsonTJ, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, SarinR, Scarpa A, Shibata T, van de Vijver M, Futreal PA, AburataniH, Bayés M, Botwell DD, Campbell PJ, Estivill X, GerhardDS, Grimmond SM, Gut I, Hirst M, López-Otín C, MajumderP, Marra M, McPherson JD, Nakagawa H, Ning Z, Puente XS,Ruan Y, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H,Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, BaderGD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigó R, GuoG, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q,López-Bigas N, Luo R, Muthuswamy L, Ouellette BF, Pearson JV,Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP,Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A,Wheeler DA, Wu H, Zhao S, Zhou G, Stein LD, Guigó R, HubbardTJ, Joly Y, Jones SM, Kasprzyk A, Lathrop M, López-Bigas N,Ouellette BF, Spellman PT, Teague JW, Thomas G, Valencia A,Yoshida T, Kennedy KL, Axton M, Dyke SO, Futreal PA, GerhardDS, Gunter C, Guyer M, Hudson TJ, McPherson JD, Miller LJ,Ozenberger B, Shaw KM, Kasprzyk A, Stein LD, Zhang J, HaiderSA, Wang J, Yung CK, Cros A, Liang Y, Gnaneshan S, GubermanJ, Hsu J, Bobrow M, Chalmers DR, Hasel KW, Joly Y, Kaan TS,Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolás P,Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, GrimmondSM, Biankin AV, Bowtell DD, Cloonan N, deFazio A, EshlemanJR, Etemadmoghadam D, Gardiner BB, Kench JG, Scarpa A,Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, McPhersonJD, Gallinger S, Tsao MS, Shaw PA, Petersen GM, MukhopadhyayD, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K,Beck T, Sam M, Timms L, Ballin V, Lu Y, Ji J, Zhang X, Chen F,Hu X, Zhou G, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z,Yu Y, Yu J, Yang H, Lathrop M, Tost J, Brennan P, Holcatova I,Zaridze D, Brazma A, Egevard L, Prokhortchouk E, Banks RE,Uhlén M, Cambon-Thomsen A, Viksna J, Ponten F, Skryabin K,Stratton MR, Futreal PA, Birney E, Borg A, B-rresen-Dale AL,Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL,Sotiriou C, Stunnenberg HG, Thoms G, van de Vijver M, van'tVeer L, Calvo F, Birnbaum D, Blanche H, Boucher P, Boyault S,Chabannon C, Gut I, Masson-Jacquemier JD, Lathrop M, PauportéI, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Thomas G,Tost J, Treilleux I, Calvo F, Bioulac-Sage P, Clément B, Decaens T,Degos F, Franco D, Gut I, Gut M, Heath S, Lathrop M, Samuel D,Thomas G, Zucman-Rossi J, Lichter P, Eils R, Brors B, Korbel JO,Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B,Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Sarin R,Rao TS, Bhan MK, Scarpa A, Pederzoli P, Lawlor RA, DelledonneM, Bardelli A, Biankin AV, Grimmond SM, Gress T, KlimstraD, Zamboni G, Shibata T, Nakamura Y, Nakagawa H, Kusada J,Tsunoda T, Miyano S, Aburatani H, Kato K, Fujimoto A, YoshidaT, Campo E, López-Otín C, Estivill X, Guigó R, de Sanjosé S, PirisMA, Montserrat E, González-Díaz M, Puente XS, Jares P, ValenciaA, Himmelbauer H, Quesada V, Bea S, Stratton MR, Futreal PA,Campbell PJ, Vincent-Salomon A, Richardson AL, Reis-Filho JS,van de Vijver M, Thomas G, Masson-Jacquemier JD, Aparicio S,Borg A, B-rresen-Dale AL, Caldas C, Foekens JA, StunnenbergHG, van't Veer L, Easton DF, Spellman PT, Martin S, Barker AD,Chin L, Collins FS, Compton CC, Ferguson ML, Gerhard DS, GetzG, Gunter C, Guttmacher A, Guyer M, Hayes DN, Lander ES,Ozenberger B, Penny R, Peterson J, Sander C, Shaw KM, SpeedTP, Spellman PT, Vockley JG, Wheeler DA, Wilson RK, HudsonTJ, Chin L, Knoppers BM, Lander ES, Lichter P, Stein LD, StrattonMR, Anderson W, Barker AD, Bell C, Bobrow M, Burke W, CollinsFS, Compton CC, DePinho RA, Easton DF, Futreal PA, GerhardDS, Green AR, Guyer M, Hamilton SR, Hubbard TJ, KallioniemiOP, Kennedy KL, Ley TJ, Liu ET, Lu Y, Majumder P, Marra M,Ozenberger B, Peterson J, Schafer AJ, Spellman PT, StunnenbergHG, Wainwright BJ, Wilson RK, Yang H. International networkof cancer genome projects. Nature 2010; 464: 993-998 [PMID:20393554 DOI: 10.1038/nature08987].
  • 9Biankin AV, Waddell N, Kassahn KS, Gingras MC, MuthuswamyLB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, ChangDK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S,Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, HolmesO, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, ChristA, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, MeadRS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM,Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, SamraJS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K,Nguyen NQ, Barbour A, Zeps N, Kakkar N, Zhao F, Wu YQ, WangM, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG,Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ,Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A,Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, OnettoN, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, GallingerS, Hruban RH, Maitra A, Iacobuzio-Donahue CA, SchulickRD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V,Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA,Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, RustAG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, ScarpaA, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, PearsonJV, McPherson JD, Gibbs RA, Grimmond SM. Pancreatic cancergenomes reveal aberrations in axon guidance pathway genes. Nature2012; 491: 399-405 [PMID: 23103869 DOI: 10.1038/nature11547].
  • 10Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P,Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, LinMT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, NikolskyY, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, JaffeeEM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR,Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G,Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathwaysin human pancreatic cancers revealed by global genomic analyses.Science 2008; 321: 1801-1806 [PMID: 18772397 DOI: 10.1126/science.1164368].

同被引文献16

引证文献3

二级引证文献8

World Journal of Gastrointestinal Oncology
2016年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部